Cargando…

Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching

PURPOSE: This study aimed to investigate the clinicopathological features and prognosis of gallbladder neuroendocrine carcinoma (GB-NEC). PATIENTS AND METHODS: Fifteen patients with GB-NEC and 171 patients with gallbladder adenocarcinoma (GB-ADC) treated in two tertiary medical centers between 2009...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Shida, Wang, Yingyi, Chen, Xiao, Zhang, Yefan, Huang, Zhen, Zhao, Jianjun, Zhou, Jianguo, Li, Zhiyu, Bi, Xinyu, Luo, Zhiwen, Cai, Jianqiang, Zhao, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049775/
https://www.ncbi.nlm.nih.gov/pubmed/32161496
http://dx.doi.org/10.2147/CMAR.S227501
_version_ 1783502511723773952
author Yan, Shida
Wang, Yingyi
Chen, Xiao
Zhang, Yefan
Huang, Zhen
Zhao, Jianjun
Zhou, Jianguo
Li, Zhiyu
Bi, Xinyu
Luo, Zhiwen
Cai, Jianqiang
Zhao, Hong
author_facet Yan, Shida
Wang, Yingyi
Chen, Xiao
Zhang, Yefan
Huang, Zhen
Zhao, Jianjun
Zhou, Jianguo
Li, Zhiyu
Bi, Xinyu
Luo, Zhiwen
Cai, Jianqiang
Zhao, Hong
author_sort Yan, Shida
collection PubMed
description PURPOSE: This study aimed to investigate the clinicopathological features and prognosis of gallbladder neuroendocrine carcinoma (GB-NEC). PATIENTS AND METHODS: Fifteen patients with GB-NEC and 171 patients with gallbladder adenocarcinoma (GB-ADC) treated in two tertiary medical centers between 2009 and 2015 were included. The clinicopathological features and prognostic risk factors of GB-NEC were analyzed retrospectively. A propensity score matching in a 1:2 ratio was used to compare the prognosis of GB-NEC and GB-ADC. RESULTS: For patients with GB-NEC, the median age of patients was 58.4 years (range 26–75), with a M:F ratio of 7:8. Based on 2010 WHO classification, ten cases were pathologically confirmed as NECs and five cases as MANECs. For TNM staging, eleven patients were stage III or above; while for Nevin staging, seven patients were stage IV or above. The 1-, 2-, and 3-year overall survival (OS) of GB-NEC were 60.0%, 38.8% and 31.1%, respectively, and the median survival time was 20.4 months. Patients with lymph node metastasis had significantly shorter survival than those without (OS: 10.4 vs 26.0 months, p<0.05). Accordingly, patients of Nevin stage III had better OS than those of Nevin stage IV (p<0.05), but other potential risk factors including gender, age, clinical symptoms, TNM stage, histopathologic subtype and treatment showed no significance. After the propensity score matching, the baseline variables had no significant difference between 15 patients with GB-NEC and 30 patients with GB-ADC, survival analysis showed GB-NEC had worse prognosis (3-year overall survival rate: 31.1% vs 63.8%, p<0.01). CONCLUSION: Nevin staging helps classify patients of GB-NEC with different prognosis and the lymph node metastasis is a strong negative prognostic factor for OS. The propensity score analysis revealed even with the similar stage and treatment, GB-NEC still had worse OS than GB-ADC.
format Online
Article
Text
id pubmed-7049775
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-70497752020-03-11 Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching Yan, Shida Wang, Yingyi Chen, Xiao Zhang, Yefan Huang, Zhen Zhao, Jianjun Zhou, Jianguo Li, Zhiyu Bi, Xinyu Luo, Zhiwen Cai, Jianqiang Zhao, Hong Cancer Manag Res Original Research PURPOSE: This study aimed to investigate the clinicopathological features and prognosis of gallbladder neuroendocrine carcinoma (GB-NEC). PATIENTS AND METHODS: Fifteen patients with GB-NEC and 171 patients with gallbladder adenocarcinoma (GB-ADC) treated in two tertiary medical centers between 2009 and 2015 were included. The clinicopathological features and prognostic risk factors of GB-NEC were analyzed retrospectively. A propensity score matching in a 1:2 ratio was used to compare the prognosis of GB-NEC and GB-ADC. RESULTS: For patients with GB-NEC, the median age of patients was 58.4 years (range 26–75), with a M:F ratio of 7:8. Based on 2010 WHO classification, ten cases were pathologically confirmed as NECs and five cases as MANECs. For TNM staging, eleven patients were stage III or above; while for Nevin staging, seven patients were stage IV or above. The 1-, 2-, and 3-year overall survival (OS) of GB-NEC were 60.0%, 38.8% and 31.1%, respectively, and the median survival time was 20.4 months. Patients with lymph node metastasis had significantly shorter survival than those without (OS: 10.4 vs 26.0 months, p<0.05). Accordingly, patients of Nevin stage III had better OS than those of Nevin stage IV (p<0.05), but other potential risk factors including gender, age, clinical symptoms, TNM stage, histopathologic subtype and treatment showed no significance. After the propensity score matching, the baseline variables had no significant difference between 15 patients with GB-NEC and 30 patients with GB-ADC, survival analysis showed GB-NEC had worse prognosis (3-year overall survival rate: 31.1% vs 63.8%, p<0.01). CONCLUSION: Nevin staging helps classify patients of GB-NEC with different prognosis and the lymph node metastasis is a strong negative prognostic factor for OS. The propensity score analysis revealed even with the similar stage and treatment, GB-NEC still had worse OS than GB-ADC. Dove 2020-02-26 /pmc/articles/PMC7049775/ /pubmed/32161496 http://dx.doi.org/10.2147/CMAR.S227501 Text en © 2020 Yan et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Yan, Shida
Wang, Yingyi
Chen, Xiao
Zhang, Yefan
Huang, Zhen
Zhao, Jianjun
Zhou, Jianguo
Li, Zhiyu
Bi, Xinyu
Luo, Zhiwen
Cai, Jianqiang
Zhao, Hong
Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching
title Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching
title_full Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching
title_fullStr Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching
title_full_unstemmed Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching
title_short Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching
title_sort clinical analysis of 15 cases of gallbladder neuroendocrine carcinoma and comparison with gallbladder adenocarcinoma using a propensity score matching
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049775/
https://www.ncbi.nlm.nih.gov/pubmed/32161496
http://dx.doi.org/10.2147/CMAR.S227501
work_keys_str_mv AT yanshida clinicalanalysisof15casesofgallbladderneuroendocrinecarcinomaandcomparisonwithgallbladderadenocarcinomausingapropensityscorematching
AT wangyingyi clinicalanalysisof15casesofgallbladderneuroendocrinecarcinomaandcomparisonwithgallbladderadenocarcinomausingapropensityscorematching
AT chenxiao clinicalanalysisof15casesofgallbladderneuroendocrinecarcinomaandcomparisonwithgallbladderadenocarcinomausingapropensityscorematching
AT zhangyefan clinicalanalysisof15casesofgallbladderneuroendocrinecarcinomaandcomparisonwithgallbladderadenocarcinomausingapropensityscorematching
AT huangzhen clinicalanalysisof15casesofgallbladderneuroendocrinecarcinomaandcomparisonwithgallbladderadenocarcinomausingapropensityscorematching
AT zhaojianjun clinicalanalysisof15casesofgallbladderneuroendocrinecarcinomaandcomparisonwithgallbladderadenocarcinomausingapropensityscorematching
AT zhoujianguo clinicalanalysisof15casesofgallbladderneuroendocrinecarcinomaandcomparisonwithgallbladderadenocarcinomausingapropensityscorematching
AT lizhiyu clinicalanalysisof15casesofgallbladderneuroendocrinecarcinomaandcomparisonwithgallbladderadenocarcinomausingapropensityscorematching
AT bixinyu clinicalanalysisof15casesofgallbladderneuroendocrinecarcinomaandcomparisonwithgallbladderadenocarcinomausingapropensityscorematching
AT luozhiwen clinicalanalysisof15casesofgallbladderneuroendocrinecarcinomaandcomparisonwithgallbladderadenocarcinomausingapropensityscorematching
AT caijianqiang clinicalanalysisof15casesofgallbladderneuroendocrinecarcinomaandcomparisonwithgallbladderadenocarcinomausingapropensityscorematching
AT zhaohong clinicalanalysisof15casesofgallbladderneuroendocrinecarcinomaandcomparisonwithgallbladderadenocarcinomausingapropensityscorematching